1. Search Result
Search Result
Results for "

replicons

" in MedChemExpress (MCE) Product Catalog:

94

Inhibitors & Agonists

1

Biochemical Assay Reagents

7

Natural
Products

15

Isotope-Labeled Compounds

1

Click Chemistry

1

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-N6798
    Myriocin
    Maximum Cited Publications
    11 Publications Verification

    Thermozymocidin; ISP-I

    HCV Antibiotic Infection
    Myriocin (Thermozymocidin), a fungal metabolite could be isolated from Myriococcum albomyces, Isaria sinclairi and Mycelia sterilia, is a potent inhibitor of serine-palmitoyl-transferase (SPT) and a key enzyme in de novo synthesis of sphingolipids. Myriocin suppresses replication of both the subgenomic HCV-1b replicon and the JFH-1 strain of genotype 2a infectious HCV, with an IC50 of 3.5 μg/mL for inhibiting HCV infection .
    Myriocin
  • HY-15602
    Ledipasvir
    30+ Cited Publications

    GS-5885

    HCV SARS-CoV Infection
    Ledipasvir (GS-5885) is an inhibitor of the hepatitis C virus NS5A, with EC50s of 34 pM and 4 pM against genotype 1a and 1b replicon, respectively. Ledipasvir is also a SARS-CoV 3CL pro inhibitor with an IC50 of 1.62 μM .
    Ledipasvir
  • HY-W063968
    RO8191
    20+ Cited Publications

    CDM-3008; RO4948191

    IFNAR JAK STAT HCV HBV Infection
    RO8191 (CDM-3008), an imidazonaphthyridine compound, is an orally active and potent interferon (IFN) receptor agonist. RO8191 directly binds to IFNα/β receptor 2 (IFNAR2) and activates IFN-stimulated genes (ISGs) expression and JAK/STAT phosphorylation. RO8191 shows antiviral activity against both HCV and EMCV with an IC50 of 200 nM for HCV replicon . RO8191 is a cccDNA modulator (CDM) through interferon-like activity and has anti-HBV activity .
    RO8191
  • HY-10237
    Boceprevir
    30+ Cited Publications

    EBP 520; SCH 503034

    HCV Protease HCV SARS-CoV Infection
    Boceprevir (EBP 520) is a potent, highly selective, orally bioavailable HCV NS3 protease inhibitor with a Ki of 14 nM in both enzyme assay and an EC90 of 350 nM in cell-based replicon assay . Boceprevir inhibits SARS-CoV-2 3CL pro activity .
    Boceprevir
  • HY-12530
    Velpatasvir
    5+ Cited Publications

    GS-5816

    HCV SARS-CoV Infection Inflammation/Immunology Cancer
    Velpatasvir (VEL, GS-5816) is a novel pan-genotypic hepatitis C virus (HCV) nonstructural protein 5A (NS5A) inhibitor with activity against genotype 1 (GT1) to GT6 HCV replicons. Velpatasvir is also a SARS-CoV 3CL pro inhibitor with an IC50 of 2.16 μM .
    Velpatasvir
  • HY-10466
    Daclatasvir
    Maximum Cited Publications
    47 Publications Verification

    BMS-790052; EBP 883

    HCV Infection
    Daclatasvir (BMS-790052) is a potent and orally active HCV NS5A protein inhibitor with EC50s range of 9-146 pM for multiple HCV replicon genotypes. Daclatasvir is also a organic anion transporting polypeptide 1B (OATP1B) and OATP1B3 inhibitor with IC50s of 1.5 µM and 3.27 µM, respectively .
    Daclatasvir
  • HY-10468
    NM107
    1 Publications Verification

    2'-C-Methylcytidine

    HCV Infection
    NM107 (2'-C-Methylcytidine) is an nucleoside inhibitor of the hepatitis C virus (HCV) NS5B polymerase, the EC50 of NM107 in the wild-type replicon cells is 1.85 μM .
    NM107
  • HY-13998
    Dasabuvir
    10+ Cited Publications

    ABT-333

    HCV DNA/RNA Synthesis Infection
    Dasabuvir (ABT-333) is a nonnucleoside hepatitis C virus (HCV) polymerase inhibitor. Dasabuvir inhibits RNA-dependent RNA polymerase encoded by the HCV NS5B gene. Dasabuvir inhibits genotype 1a (strain H77) and 1b (strain Con1) replicons, with EC50 values of 7.7 and 1.8 nM, respectively .
    Dasabuvir
  • HY-10465
    Daclatasvir dihydrochloride
    Maximum Cited Publications
    47 Publications Verification

    BMS-790052 dihydrochloride; EBP 883 dihydrochloride

    HCV Infection
    Daclatasvir dihydrochloride (BMS-790052 dihydrochloride) is a potent and orally active HCV NS5A protein inhibitor with EC50s range of 9-146 pM for multiple HCV replicon genotypes. Daclatasvir dihydrochloride is also an organic anion transporting polypeptide 1B (OATP1B) and OATP1B3 inhibitor with IC50s of 1.5 μM and 3.27 μM, respectively .
    Daclatasvir dihydrochloride
  • HY-109035
    Inarigivir soproxil
    1 Publications Verification

    SB9200; GS-9992

    HCV HBV Infection
    Inarigivir soproxil (SB9200) is an agonist of innate immunity and shows potent antiviral activity against resistant HCV variants, with EC50s of 2.2 and 1.0 μM for HCV 1a/1b in cells of genotype 1 HCV replicon systems. Inarigivir soproxil, an orally bioavailable proagent of SB 9000, has broad-spectrum antiviral activity against RNA viruses including HCV, norovirus, respiratory syncytial virus and influenza and HBV .
    Inarigivir soproxil
  • HY-125371
    2'-C-Methyladenosine
    2 Publications Verification

    HCV Infection Inflammation/Immunology
    2'-C-Methyladenosine is an inhibitor of hepatitis C virus (HCV) replication. 2'-C-Methyladenosine inhibits HCV replicon and NS5B-catalyzed RNA synthesis with IC50 values of 0.3μM and 1.9 μM, respectively. 2'-C-Methyladenosine also potently inhibits LRV1 in Leishmania guyanensis (Lgy) and Leishmania braziliensis .
    2'-C-Methyladenosine
  • HY-101662

    ABT-530

    HCV Infection
    Pibrentasvir is a novel and pan-genotypic hepatitis C virus (HCV) NS5A inhibitor with EC50s ranging from 1.4 to 5.0 pM against HCV replicons containing NS5A from genotypes 1 to 6.
    Pibrentasvir
  • HY-15602B
    Ledipasvir D-tartrate
    30+ Cited Publications

    GS-5885 D-tartrate

    HCV Infection
    Ledipasvir D-tartrate is an inhibitor of the hepatitis C virus NS5A, with EC50 values of 34 pM against GT1a and 4 pM against GT1b replicon.
    Ledipasvir D-tartrate
  • HY-15602A
    Ledipasvir (acetone)
    30+ Cited Publications

    GS-5885 (acetone)

    HCV Infection
    Ledipasvir acetone (GS-5885 acetone) is the active ingredient of Ledipasvir. Ledipasvir is an inhibitor of the hepatitis C virus NS5A, with EC50 values of 34 pM against GT1a and 4 pM against GT1b replicon.
    Ledipasvir (acetone)
  • HY-15236
    PSI-6206
    3 Publications Verification

    RO 2433; GS-331007

    HCV Infection
    PSI-6206 (RO 2433) is the deaminated derivative of PSI-6130, which is a potent and selective inhibitor of HCV NS5B polymerase. PSI-6206 low potently inhibits HCV replicon with EC90 of >100 μM.
    PSI-6206
  • HY-75800
    Lomibuvir
    2 Publications Verification

    VX-222

    DNA/RNA Synthesis HCV Infection
    Lomibuvir (VX-222), a selective, non-nucleoside polymerase inhibitor, targets thumb pocket 2 of the HCV NS5B polymerase (RdRp) with a Kd of 17 nM. Lomibuvir inhibits the 1b/Con1 HCV subgenomic replicon with an EC50 of 5.2 nM. Lomibuvir preferentially inhibits elongative RNA synthesis rather than de novo-initiated RNA synthesis .
    Lomibuvir
  • HY-10244
    MK-0608
    1 Publications Verification

    HCV Infection
    MK-0608 is a potent and orally bioavailable inhibitor of HCV replication in vitro with an EC50 of 0.3 μM (EC90=1.3 μM) in the subgenomic-replicon assay .
    MK-0608
  • HY-15005S1
    Sofosbuvir-d6
    1 Publications Verification

    PSI-7977-d6; GS-7977-d6

    Isotope-Labeled Compounds HCV Infection
    Sofosbuvir-d6 is the deuterium labeled Sofosbuvir. Sofosbuvir (PSI-7977) is an active inhibitor of HCV RNA replication in the HCV replicon assay, demonstrates potent anti-hepatitis C virus (HCV) activity.
    Sofosbuvir-d6
  • HY-135867E
    NHC-triphosphate tetraammonium
    5+ Cited Publications

    CHIKV Endogenous Metabolite Enterovirus HCV Topoisomerase SARS-CoV Infection
    NHC-triphosphate tetraammonium is an active phosphorylated intracellular metabolite of β-d-N4-Hydroxycytidine (NHC) (HY-125033) as a triphosphate form . NHC-triphosphate tetraammonium is a weak alternative substrate for the viral polymerase and can be incorporated into HCV replicon RNA .
    NHC-triphosphate tetraammonium
  • HY-146344

    DNA/RNA Synthesis Infection
    Antiviral agent 17 is an anti-infection agent. Antiviral agent 17 retains its antiviral effect in a human replicon assay (EC50 = 0.015 μM). Antiviral agent 17 results in good antiviral activity against murine norovirus with an EC50 of 7 nM. . Antiviral agent 17 has the potential for the research of infectious and malignant diseases .
    Antiviral agent 17
  • HY-124191

    PPI-668 hydrochloride

    HCV Infection
    Ravidasvir hydrochloride (PPI-668 hydrochloride) is a pan-genotypic inhibitor for hepatitis C virus (HCV) NS5A protein. Ravidasvir hydrochloride inhibits the replication of HCV, with EC50 of 0.12, 0.01 and 1.14 nM, for HCV gt-1a, gt-1b, and gt-3a replicons, respectively. Ravidasvir hydrochloride exhibits good pharmacokinetic characters in rats .
    Ravidasvir hydrochloride
  • HY-W540972

    Primuline

    Fluorescent Dye HCV Dengue Virus Infection
    Primulin is a versatile fluorescent dye and bioactive compound widely used in analytical, biological, botanical and virological studies. Primulin acts as a versatile stain that labels plant cell walls and differentiates live and dead spermatozoa via distinct fluorescence patterns. Primulin exhibits strong albumin‑binding capacity. Primulin acts as a retrograde axonal tracer in neurobiological investigations. Primulin and its derivatives inhibit HCV NS3, block dengue virus NS3-mediated ATP hydrolysis, and disrupt HCV replicase assembly .
    Primulin
  • HY-10444
    R-1479
    3 Publications Verification

    4'-Azidocytidine

    HCV DNA/RNA Synthesis Infection
    R-1479 (4'-Azidocytidine), a nucleoside analogue, is a specific inhibitor of RNA-dependent RNA polymerase (RdRp) of HCV. R-1479 inhibits HCV replication in the HCV subgenomic replicon system (IC50=1.28 μM) . R-1479 is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
    R-1479
  • HY-10118
    Filibuvir
    4 Publications Verification

    HCV DNA/RNA Synthesis Infection
    Filibuvir is an orally active, selective non-nucleoside inhibitor of the HCV nonstructural 5B protein (NS5B) RNA-dependent RNA polymerase (RdRp). Filibuvir binds noncovalently in the thumb II allosteric pocket of NS5B. Filibuvir inhibits genotype 1a and 1b replicons with EC50s of 59 nM for both isoforms, respectively . Filibuvir preferentially inhibits elongative RNA synthesis and potently decreases viral RNA accumulation .
    Filibuvir
  • HY-N0620
    Mulberroside C
    1 Publications Verification

    HCV Infection
    Mulberroside C is one of the main bioactive constituents in mulberry (Morus alba L.) . Mulberroside C is a HCV replicon inhibitor. Antiviral activity .
    Mulberroside C
  • HY-136797

    Dengue Virus Infection
    BP13944 is a potential small molecule inhibitor discovered by high-throughput screening. It can effectively inhibit the expression of dengue virus (DENV) replicons with an EC50 value of 1.03±0.09 μM. BP13944 can inhibit the replication or viral RNA synthesis of all four serotypes of DENV, but is ineffective against Japanese encephalitis virus. BP13944 may target the DENV NS3 protease, and the E66G amino acid substitution in the NS3 protease region will cause the virus to become resistant to BP13944. BP13944 has no obvious cytotoxicity. As there is currently no effective dengue vaccine and treatment, BP13944, as an effective small molecule inhibitor, may become a potential agent for the treatment of dengue in the future.
    BP13944
  • HY-13465
    VCH-916
    1 Publications Verification

    HCV Infection
    VCH-916 is a thiophene derivative and non-nucleoside inhibitor of HCV NS5B polymerase with sub-micromolar IC50 values versus genotype 1a and 1b replicons. VCH-916 binds to Thumb Site II. VCH-916 can be used for the research of hepatitis c virus (hcv) infection .
    VCH-916
  • HY-16784
    Samatasvir
    1 Publications Verification

    IDX719; IDX18719

    HCV HCV Protease Infection
    Samatasvir (IDX71) is a potent, orally active NS5A inhibitor of HCV replication. Samatasvir is effective and selective against infectious HCV and replicons, with EC50s falling within a tight range of 2 to 24 pM in genotype 1 through 5 replicons .
    Samatasvir
  • HY-138305

    HCV Infection Inflammation/Immunology
    HCV-IN-31 (compound 4) is a HCV inhibitor, with an EC50/EC95 of 15.7 μM for HCV replicon .
    HCV-IN-31
  • HY-10465R

    BMS-790052 dihydrochloride (Standard); EBP 883 dihydrochloride (Standard)

    Reference Standards HCV Infection
    Daclatasvir (dihydrochloride) (Standard) is the analytical standard of Daclatasvir (dihydrochloride). This product is intended for research and analytical applications. Daclatasvir dihydrochloride (BMS-790052 dihydrochloride) is a potent and orally active HCV NS5A protein inhibitor with EC50s range of 9-146 pM for multiple HCV replicon genotypes. Daclatasvir dihydrochloride is also an organic anion transporting polypeptide 1B (OATP1B) and OATP1B3 inhibitor with IC50s of 1.5 µM and 3.27 µM, respectively .
    Daclatasvir dihydrochloride (Standard)
  • HY-135867

    CHIKV Endogenous Metabolite Enterovirus HCV Topoisomerase SARS-CoV Infection
    NHC-triphosphate is an active phosphorylated intracellular metabolite of β-d-N4-Hydroxycytidine (NHC) (HY-125033) as a triphosphate form . NHC-triphosphate is a weak alternative substrate for the viral polymerase and can be incorporated into HCV replicon RNA .
    NHC-triphosphate
  • HY-15602C

    GS-5885 hydrochloride

    HCV SARS-CoV Infection
    Ledipasvir (GS-5885) hydrochloride is an inhibitor of the hepatitis C virus NS5A, with EC50s of 34 pM and 4 pM against genotype 1a and 1b replicon, respectively. Ledipasvir hydrochloride is also a SARS-CoV 3CL pro inhibitor with an IC50 of 1.62 μM .
    Ledipasvir hydrochloride
  • HY-12530R

    GS-5816 (Standard)

    Reference Standards HCV SARS-CoV Infection Inflammation/Immunology Cancer
    Velpatasvir (Standard) is the analytical standard of Velpatasvir. This product is intended for research and analytical applications. Velpatasvir (VEL, GS-5816) is a novel pan-genotypic hepatitis C virus (HCV) nonstructural protein 5A (NS5A) inhibitor with activity against genotype 1 (GT1) to GT6 HCV replicons. Velpatasvir is also a SARS-CoV 3CL pro inhibitor with an IC50 of 2.16 μM .
    Velpatasvir (Standard)
  • HY-N8188

    HCV HCV Protease Infection
    Dehydrojuncusol, a potent HCV inhibitor, targets HCV NS5A and is able to inhibit RNA replication of replicons harboring resistance mutations to anti-NS5A direct-acting antivirals. Dehydrojuncusol significantly inhibits HCV infection when added after virus inoculation of HCV genotype 2a (EC50=1.35?μM) .
    Dehydrojuncusol
  • HY-15602D

    GS-5885 (diacetone)

    HCV Infection
    Ledipasvir diacetone (GS-5885 diacetone) is the active ingredient of Ledipasvir. Ledipasvir is an inhibitor of the hepatitis C virus NS5A, with EC50 values of 34 pM against GT1a and 4 pM against GT1b replicon.
    Ledipasvir (diacetone)
  • HY-15005A

    HCV Infection
    PSI-7976 is the isomer of PSI-7977. PSI-7977 is an active inhibitor of HCV RNA replication in the HCV replicon assay, demonstrates potent anti-hepatitis C virus (HCV) activity.
    PSI-7976
  • HY-135867A

    CHIKV Endogenous Metabolite Enterovirus HCV Topoisomerase Infection
    NHC-triphosphate tetrasodium is an active phosphorylated intracellular metabolite of β-d-N4-Hydroxycytidine (NHC) (HY-125033) as a triphosphate form . NHC-triphosphate tetrasodium is a weak alternative substrate for the viral polymerase and can be incorporated into HCV replicon RNA .
    NHC-triphosphate tetrasodium
  • HY-15602AS

    GS-5885-d6 hydrochloride

    HCV Isotope-Labeled Compounds Infection
    Ledipasvir-d6 hydrochloride is deuterated labeled Ledipasvir acetone (HY-15602A). Ledipasvir acetone (GS-5885 acetone) is the active ingredient of Ledipasvir. Ledipasvir is an inhibitor of the hepatitis C virus NS5A, with EC50 values of 34 pM against GT1a and 4 pM against GT1b replicon.
    Ledipasvir-d6 hydrochloride
  • HY-14391

    GS-558093

    HCV Infection
    PSI-353661 (GS-558093) is a purine nucleotide NS5B polymerase inhibitor against HCV infection. PSI-353661 shows EC90s of 8 nM and 11 nM for wild type and S282T resistant replicons of HCV. PSI-353661 can produce high concentrations of the active triphosphate in primary human hepatocytes .
    PSI-353661
  • HY-112047

    GSK2878175

    HCV Infection
    GSK8175 is a non-nucleoside polymerase (NS5B) inhibitor of hepatitis C virus (HCV). GSK8175 is a sulfonamide- N-benzoxaborole analog with low in vivo clearance across preclinical species and broad-spectrum activity against HCV replicons .
    GSK8175
  • HY-131905S

    Isotope-Labeled Compounds HCV Protease HCV Infection Inflammation/Immunology Cancer
    BMS-986144 is a third-generation, pan-genotype (GT) NS3/4A protease inhibitor. BMS-986144 inhibits HCV replicon with EC50s of 2.3, 0.7, 1.0, 12, 8.0, and 5.8 nM for GT-1a, GT-1b, GT-2a, GT-3a, 1a R155X, and 1b D168V, respectively. BMS-986144 has the potential for the research of HCV infection .
    BMS-986144
  • HY-U00213

    R803

    HCV Infection
    Furaprofen (R803) is an effective HCV replication inhibitor. Furaprofen (R803) is substantially more potent against genotype 1a and 1b replicons (EC50, ~30 nM) than against the genotype 2a replicon (EC50, ~1,000 nM).
    Furaprofen
  • HY-111087

    HCV Protease Infection Inflammation/Immunology
    AZD-7295 is a HCV NS5A protein inhibitor, with an EC50 of 7 nM for GT-1b replicon .
    AZD-7295
  • HY-15005B

    Drug Metabolite Others
    Sofosbuvir impurity C is an impurity of Sofosbuvir, Sofosbuvir is an active inhibitor of HCV RNA replication in the HCV replicon assay, demonstrates potent anti-hepatitis C virus (HCV) activity.
    Sofosbuvir impurity C
  • HY-15005S

    PSI-7977-13C,d3; GS-7977-13C,d3

    Isotope-Labeled Compounds HCV Infection
    Sofosbuvir- 13C,d3 is the deuterium labeled Sofosbuvir. Sofosbuvir (PSI-7977) is an active inhibitor of HCV RNA replication in the HCV replicon assay, demonstrates potent anti-hepatitis C virus (HCV) activity.
    Sofosbuvir-13C,d3
  • HY-135867F
    NHC-diphosphate triammonium
    1 Publications Verification

    CHIKV Endogenous Metabolite Enterovirus HCV Topoisomerase SARS-CoV Infection
    NHC-diphosphate triammonium is an active phosphorylated intracellular metabolite of β-d-N4-Hydroxycytidine (NHC) (HY-125033) as a diphosphate form . NHC-diphosphate triammonium is a weak alternative substrate for the viral polymerase and can be incorporated into HCV replicon RNA .
    NHC-diphosphate triammonium
  • HY-12633

    HCV Inflammation/Immunology
    GS-6620 is potent and selective HCV inhibitor. GS-6620 inhibits HCV replication in genotype 1-6 subgenomic replicons and genotype 2a infectious virus, with EC50 values of 0.048-0.68 μM. GS-6620 can be used for the researches of infection and inflammation, such as Hepatitis C Virus (HCV) .
    GS-6620
  • HY-15602S

    GS-5885-d6

    HCV SARS-CoV Infection
    Ledipasvir-d6 is the deuterium labeled Ledipasvir. Ledipasvir (GS-5885) is an inhibitor of the hepatitis C virus NS5A, with EC50s of 34 pM and 4 pM against genotype 1a and 1b replicon, respectively. Ledipasvir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 1.62 μM .
    Ledipasvir-d6
  • HY-13998A

    ABT-333 sodium

    HCV DNA/RNA Synthesis Infection
    Dasabuvir (ABT-333) sodium is a nonnucleoside hepatitis C virus (HCV) polymerase inhibitor. Dasabuvir sodium inhibits RNA-dependent RNA polymerase encoded by the HCV NS5B gene. Dasabuvir sodium inhibits genotype 1a (strain H77) and 1b (strain Con1) replicons, with EC50 values of 7.7 and 1.8 nM, respectively .
    Dasabuvir sodium
  • HY-102030

    HCV Infection
    BMS-961955 is an orally active inhibitor of HCV NS5B polymerase. BMS-961955 exhibits potent inhibitory activity against HCV genotype 1 (GT-1a/1b) replicons with EC50s of 4.3 nM and 7.9 nM, respectively. BMS-961955 can be used for the study of HCV infection .
    BMS-961955

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: